BRPI0713421A2 - Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero - Google Patents

Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero Download PDF

Info

Publication number
BRPI0713421A2
BRPI0713421A2 BRPI0713421-5A BRPI0713421A BRPI0713421A2 BR PI0713421 A2 BRPI0713421 A2 BR PI0713421A2 BR PI0713421 A BRPI0713421 A BR PI0713421A BR PI0713421 A2 BRPI0713421 A2 BR PI0713421A2
Authority
BR
Brazil
Prior art keywords
formulation
antibody
methods
liofolized
liophilization
Prior art date
Application number
BRPI0713421-5A
Other languages
English (en)
Inventor
Agarkhed Meera
Srivastava Arvind
Goldstein Joel
Original Assignee
Imclone Systems Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Incorporated filed Critical Imclone Systems Incorporated
Publication of BRPI0713421A2 publication Critical patent/BRPI0713421A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

FORMULAçãO LIOFILIZADA, FORMULAçãO AQUOSA ADEQUADA PARA A LIOFILIZAçãO, E, MéTODOS PARA ESTABILIZAR UM ANTICORPO E PARA TRATAR UM MAMìFERO. Em uma forma de realização, a presente invenção fornece uma formulação liofilizada estável que compreende um anticorpo anti-EGFR, preferivelmente cetuximab; ácido lactobiónico; e um tampão, preferivelmente histidina. Em uma forma de realização preferida, a presente invenção fornece uma formulação liofilizada estável que compreende cerca de 50 mg/ml a cerca de 140 mg/ml de ERBITUX?, cerca de 0,125% de ácido lactobiónico, cerca de 25 mM de tampão de histidina em um pH de cerca de 6,0, cerca de 0,005% de Tween 80 e cerca de 1,875% de glicina.
BRPI0713421-5A 2006-06-14 2007-06-13 Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero BRPI0713421A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14
US60/813958 2006-06-14
PCT/US2007/071119 WO2007147001A2 (en) 2006-06-14 2007-06-13 Lyophilized formulations of anti-egfr antibodies

Publications (1)

Publication Number Publication Date
BRPI0713421A2 true BRPI0713421A2 (pt) 2012-03-13

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713421-5A BRPI0713421A2 (pt) 2006-06-14 2007-06-13 Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero

Country Status (18)

Country Link
US (1) US20100158925A1 (pt)
EP (1) EP2029163A4 (pt)
JP (1) JP2009540015A (pt)
KR (1) KR20090021298A (pt)
CN (1) CN101466404A (pt)
AU (1) AU2007260769A1 (pt)
BR (1) BRPI0713421A2 (pt)
CA (1) CA2654794A1 (pt)
CR (1) CR10493A (pt)
EA (1) EA200870538A1 (pt)
EC (1) ECSP088962A (pt)
IL (1) IL195794A0 (pt)
MA (1) MA30515B1 (pt)
MX (1) MX2008015852A (pt)
NO (1) NO20085131L (pt)
TN (1) TNSN08511A1 (pt)
WO (1) WO2007147001A2 (pt)
ZA (1) ZA200810456B (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
EA201001467A1 (ru) 2008-03-14 2011-06-30 Биокон Лимитед Моноклональное антитело и способ его использования
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
AU2010320515B2 (en) * 2009-11-20 2013-05-02 Biocon Limited Formulations of antibody
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
MX2012007676A (es) * 2009-12-29 2012-08-03 Hoffmann La Roche Nueva formulacion de anticuerpo.
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
CN103108658B (zh) * 2010-07-02 2015-08-19 米迪缪尼有限公司 抗体制剂
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CA2920368C (en) 2013-07-23 2023-03-21 Centro De Inmunologia Molecular Use of a cd6 binding partner and method based thereon
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
MX2016003256A (es) * 2013-09-12 2016-06-07 Halozyme Inc Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
JP7020909B2 (ja) 2014-07-25 2022-02-16 シトムクス セラピューティクス，インコーポレイティド 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
WO2016024227A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CN106470697B (zh) * 2014-09-16 2019-10-25 兴盟生物医药(苏州)有限公司 抗egfr抗体以及其用途
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
SG11201704741PA (en) * 2014-12-22 2017-07-28 Systimmune Inc Bispecific tetravalent antibodies and methods of makiing and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN108602827B (zh) 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
US10940185B2 (en) 2016-12-28 2021-03-09 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
CN110831621A (zh) * 2017-04-18 2020-02-21 雷迪博士实验室有限公司 稳定的液体药物组合物
CA3287794A1 (en) 2017-10-14 2025-10-27 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
SG11202011538RA (en) * 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
CN114423499A (zh) * 2019-06-06 2022-04-29 佳努克斯治疗公司 与肿瘤激活的t细胞衔接子相关的组合物和方法
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
WO2022035866A1 (en) 2020-08-11 2022-02-17 Janux Therapeutics, Inc. Cleavable linker compositions and methods
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
WO2024058201A1 (ja) * 2022-09-16 2024-03-21 国立研究開発法人量子科学技術研究開発機構 放射性医薬組成物の中間体の製造方法、放射性医薬組成物の中間体の精製用キット

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
EP2332990A1 (en) * 2004-03-19 2011-06-15 Imclone LLC Human anti-epidermal growth factor receptor antibody
AU2007215012A1 (en) * 2006-02-15 2007-08-23 Imclone Llc Antibody formulation

Also Published As

Publication number Publication date
JP2009540015A (ja) 2009-11-19
CA2654794A1 (en) 2007-12-21
KR20090021298A (ko) 2009-03-02
AU2007260769A1 (en) 2007-12-21
TNSN08511A1 (en) 2010-04-14
WO2007147001A3 (en) 2008-07-10
NO20085131L (no) 2009-03-13
MX2008015852A (es) 2009-02-23
EA200870538A1 (ru) 2009-04-28
EP2029163A4 (en) 2010-08-11
ZA200810456B (en) 2009-12-30
MA30515B1 (fr) 2009-06-01
EP2029163A2 (en) 2009-03-04
US20100158925A1 (en) 2010-06-24
ECSP088962A (es) 2009-01-30
IL195794A0 (en) 2011-08-01
CR10493A (es) 2009-02-26
WO2007147001A2 (en) 2007-12-21
CN101466404A (zh) 2009-06-24

Similar Documents

Publication Publication Date Title
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
BRPI0514340A (pt) formulações de estabilização
EA200970880A1 (ru) Стабильные композиции на основе антител
BRPI0818765A8 (pt) Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
RU2013137740A (ru) Жидкая композиция, содержащая антитело высокой концентрации
WO2007113648A3 (en) Ctla4 antibody combination therapy
EA201100072A1 (ru) Новые композиции и способы
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
BRPI0516408B8 (pt) derivados de estilbeno e seu uso para ligação e formação de imagem de placas de amilóide
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112014009785A8 (pt) método para tratar ou reduzir efp
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
BR112013019513A2 (pt) métodos para o tratamento de úlceras diabéticas do pé
BRPI0720230A2 (pt) Uso de uma formulação nutricional oralmente administrável, formulação nutricional, método para tratar um distúrbio desenvolvimental penetrante, e, composição
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: IMCLONE LLC (US)

Free format text: NOME ALTERADO DE: IMCLONE SYSTEMS INCORPORATED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE.